Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
| Autor: | Shulamith Rizel, Michelle Leviov, Debbie M Jakubowski, David B. Geffen, Ora Rosengarten, Mariana Steiner, Steven Shak, Avital Bareket-Samish, Noa Ben-Baruch, Margarita Tokar, Amit Itay, Daniela Katz, Julie Baron, Nicky Liebermann, Salomon M. Stemmer, Lior Soussan-Gutman, Beatrice Uziely, Bella Nisenbaum, Georgeta Fried |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Cancer therapy medicine.medical_treatment Recurrence score lcsh:RC254-282 Gastroenterology Article 03 medical and health sciences Breast cancer 0302 clinical medicine Er breast cancer Internal medicine Medicine Pharmacology (medical) Radiology Nuclear Medicine and imaging In patient Chemotherapy business.industry Exploratory analysis lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Confidence interval 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cohort business |
| Zdroj: | npj Breast Cancer, Vol 5, Iss 1, Pp 1-6 (2019) NPJ Breast Cancer |
| ISSN: | 2374-4677 |
| DOI: | 10.1038/s41523-019-0137-3 |
| Popis: | The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer (BC). Long-term data from real-life clinical practice where treatment was guided by the RS result are lacking. We performed exploratory analysis of the Clalit Health Services (CHS) registry, which included all CHS patients with node-negative ER+ HER2-negative BC who underwent RS testing between 1/2006 and 12/2009 to determine 10-year Kaplan–Meier estimates for distant recurrence/BC-specific mortality (BCSM) in this cohort. The analysis included 1365 patients. Distribution of RS results: RS 0–10, 17.8%; RS 11–25, 62.5%; RS 26–100, 19.7%. Corresponding CT use: 0, 9.4, and 69.9%. Ten-year distant recurrence rates in patients with RS 0–10, 11–25, and 26–100: 2.6% (95% confidence interval [CI], 1.1–6.2%), 6.1% (95% CI, 4.4–8.6%), and 13.1% (95% CI, 9.4–18.3%), respectively (P P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|